(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Slides:

Advertisements

Similar presentations

Genetics In Breast Cancer

Advertisements

Nat. Rev. Clin. Oncol. doi: /nrclinonc

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

(A) Timeline of the patient’s clinical events and interventions.

Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) analysis of MET and KRAS. For IHC, the specific MET antibody (Met (D1C2) XP Rabbit.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.

Figure 2 Schema for the phase II Randomized Observation versus

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. DKTK MASTER is an example of whole-exome and.

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Progesterone receptor nuclear morphology patterns in breast cancer.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Therapeutic validation in orthotopic lung PDX. (A).

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Figure 2 Logistical requirements for autologous

Flow chart of the used methodology adapted from Moher et al

The decision tree with the two alternatives.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

(A) Safety profile overview.

Detection rate for EGFR mutations in cfDNA.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

(A) Number of KRAS mutations detected by mutation concentration by each technology with 100 copies mutant allele frequency. (A) Number of KRAS mutations.

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Methods distribution among the three EQAs

Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.

Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

Distribution of TMB and neoantigen load across tumour types.

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

Molecular spectra of BTC

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

Comparison of the LL95%CI rule to a PE threshold for maximal RB classification: sensitivity and specificity for the MCBS LL95%CI ≤0.65 rule versus the.

Programmed cell death ligand-1 (PD-L1) immunohistochemistry for pulmonary adenocarcinoma tissues. Programmed cell death ligand-1 (PD-L1) immunohistochemistry.

Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Application of 5-aminolevulinic acid (5-ALA)

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Gender representation in all international congresses (reference year 2016). Gender representation in all international congresses (reference year 2016).

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.

Proportion of continuous, intermittent, and limited (

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

On the left, Euler-Venn diagram of point mutations detected by lbNGS and ttNGS on matched genes from the same patients; on the right, the percentage of.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.

Heterogeneity in the natural history of triple negative breast cancer.

PRAME-specific CD4+ T-cell (TNF-α+/IFN-γ+) immunogenicity scores and cellular response prior to treatment and postdose 4 (ATP cohort for immunogenicity).

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

(A) Survival curves according to clinical response.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

ICOS+ and activated CD4+ T cells are dominant, tumour tissue-specific T cell populations in both mismatch repair-deficient and repair-proficient colorectal.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (A) Distribution of dMMR proteins in the entire cohort and per tumour type.

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment. (A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment. Only point mutations reported in COSMIC database are shown (left panel) together with complete copy number profile (right panel). (B) MYC gene amplification by fluorescence in situ hybridisation (FISH). Multiple red signals relative to MYC gene are present in breast cancer nuclei. Magnification: 100x. CSF, cerebrospinal fluid; ctDNA, circulating tumour DNA; FISH, fluorescence in situ hybridisation; PBMC, peripheral blood mononuclear cells; T-DM1, trastuzumab emtansine; WES, whole exome sequencing. Giulia Siravegna et al. ESMO Open 2017;2:e000253 Copyright © European Society for Medical Oncology. All rights reserved.